Essential role of PDGFRα-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo role of PDGFRα during angiogenesis

Circulation Research

Volumn 94, Issue 9, 2004, Pages 1186-1194

  Tsutsumi, Norifumi ^a   Yonemitsu, Yoshikazu ^a   Shikada, Yasunori ^a   Onimaru, Mitsuho ^a   Tanii, Mitsugu ^a   Okano, Shinji ^a   Kaneko, Kazuhiro ^a   Hasegawa, Mamoru ^b   Hashizume, Makoto ^a   Maehara, Yoshihiko ^a   Sueishi, Katsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b DNAVEC Research Inc   (Japan)

Author keywords

Angiogenesis; Mesenchymal cells; P70S6K; PDGF AA; Tumor

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RAPAMYCIN; S6 KINASE; SCATTER FACTOR; VASCULOTROPIN; EPIDERMAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET-DERIVED GROWTH FACTOR A; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; LIMB ISCHEMIA; MALE; MALIGNANT NEOPLASTIC DISEASE; MESENCHYME CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; ANGIOGENESIS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL HYPOXIA; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HINDLIMB; ISCHEMIA; LIVER TUMOR; MESODERM; METABOLISM; MOUTH TUMOR; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; STROMA CELL; VASCULARIZATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HEPATOCYTE GROWTH FACTOR; HINDLIMB; HUMANS; ISCHEMIA; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MESODERM; MICE; MICE, INBRED C57BL; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLATELET-DERIVED GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; STROMAL CELLS;

EID: 2442694008     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000126925.66005.39     Document Type: Article

References (30)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149-153.
3. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94:883-893.
4. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A. 1988;95:8795-8800.
5. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, D'Amato R, Folkman J, Mulligan RC. Comparative evaluation of the antitumor activity of anti-angiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A. 2001;98:4605-4610.
6. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 2000;60:2169-2177.
7. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelki C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135.
8. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K, Hou X, Nagai Y, Hasegawa M, Sugimachi K, Sueishi K. Gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of VEGF165 but not of FGF-2. Circ Res. 2002; 90:966-973.
9. Onimaru M, Yonemitsu Y, Tanii M, Nakagawa K, Masaki I, Okano S, Ishibashi H, Shirasuna K, Hasegawa M, Sueishi K. FGF-2 gene transfer can stimulate HGF expression, irrespective of hypoxia-mediated down regulation in ischemic limbs. Circ Res. 2002;91:723-730.
10. Compagni A, Wilgenbus P, Impagnatiello MA, Cotton M, Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 2000;60:7163-7169.
11. Yonemitsu Y, Kitson C, Ferrari S, Farley R, Griesenbach U, Judd D, Steel R, Scheid P, Zhu J, Jeffery PK, Kato A, Hasan MK, Nagai Y, Masaki I, Fukumura M, Hasegawa M, Geddes DM, Alton EW. Efficient gene transfer to the airway epithelium using recombinant Sendai virus. Nat Biotechnol. 2000;18:970-973.
12. Masaki I, Yonemitsu Y, Komori K, Ueno H, Nakashima Y, Nakagawa K, Fukumura M, Kato A, Hasan MK, Nagai Y, Sugimachi K, Hasegawa M, Sueishi K. Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system. FASEB J. 2001;15:1294-1296.
13. Yamashita A, Yonemitsu Y, Okano S, Nakagawa K, Nakashima Y, Irisa T, Iwamoto Y, Nagai Y, Hasegawa M, Sueishi K. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol. 2002;168:450-457.
14. Shoji F, Yonemitsu Y, Okano S, Yoshino I, Nakagawa K, Nakashima Y, Hasegawa M, Sugimachi K, Sueishi K. Airway-directed gene transfer of interleukin-10 using recombinant Sendai virus effectively prevents post-transplantation fibrous airway obliteration in mice. Gene Ther. 2003;10: 213-218.
15. Jin CH, Kusuhara K, Yonemitsu Y, Nomura A, Okano S, Takeshita H, Hasegawa M, Sueishi K, Hara T. Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells. Gene Ther. 2003;10:272-280.
16. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest. 1999;103:341-345.
17. Siegbahn A, Hammacher A, Westermark B, Heldin CH. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J Clin Invest. 1990; 85:916-920.
18. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U. PDGF-C is a new protease-activated ligand for the PDOF ct-receptor. Nat Cell Biol. 2000;2:302-309.
19. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol. 1994;145:1023-1029.
20. Cao R, Brakenhielm E, Li X, Pietras K, Widenfalk J, Ostman A, Eriksson U, Cao Y. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-αα and -αβ receptors. FASEB J. 2002;16:1575-1583.
21. Vinals F, Chambard JC, Pouyssegur J. p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem. 1999;274:26776-26782.
22. Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothefial growth factor. J Cell Physiol. 1999;178:235-246.
23. Bostrom H, Willetts K, Pekny M, Leveen P, Lindahl P, Hedstrand H, Pekna M, Hellstrom M, Gebre-Medhin S, Schalling M, Nilsson M, Kurland S, Tornell J, Heath JK, Betsholtz C. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell. 1996;85:863-873.
24. Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res. 1998;83:852-859.
25. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res. 2000; 6:1900-1908.
26. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol. 2001;28:S27-S33.
27. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287-1295.
28. van den Bos C, Mosca JD, Winkles J, Kerrigan L, Burgess WH, Marshak DR. Human mesenchymal stem cells respond to fibroblast growth factors. Hum Cell. 1997;10:45-50.
29. Al-Khaldi A, Eliopoulos N, Martineau D, Lejeune L, Lachapelle K, Galipeau I. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther. 2003;10: 621-629.
30. Brara PS, Moussavian M, Grise MA, Reilly JP, Fernandez M, Schatz RA, Teirstein PS. Pilot trial of oral rapamycin for recalcilrant restenosis. Circulation. 2003;107:1722-1724.